I read where there are less than 20000 US cases of neuroblastoma with approximately 700 new cases per year. If ponatinib turns out to be the DOC for this indication that is quite a sizable market. It seems as if this "dirty drug" isnt quite as bad as some had thought. Eventually imo it will be the multi billion dollar blockbuster we had hoped and both Denner and the BPs know it. The price of the buyout should reflect that new reality.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.